GlassScriptPhysician profile
Ananthi Rathinam
NPI 1811952443
$2,699.84
in general payments reported to CMS, 2019-2025
28 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $688 · 2021: $636 · 2022: $206 · 2023: $297 · 2024: $125 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $543.77 | 2019-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $428.12 | 2019-2021 | |
| Ucb, INC. | $264.62 | 2020-2024 | Briviact |
| Corium, LLC | $185.14 | 2023 | Azstarys |
| Greenwich Biosciences, INC. | $173.58 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.16 | 2020-2022 | |
| Livanova USA, INC. | $94.75 | 2020-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $89.79 | 2020 | |
| Eisai INC. | $84.48 | 2019-2021 | |
| Allergan, INC. | $77.75 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $66.64 | 2022-2023 | Epidiolex |
| Cranial Technologies, INC | $61.90 | 2020-2022 | |
| Zogenix INC. | $58.89 | 2021 | |
| Ironshore Pharmaceuticals INC. | $50.97 | 2022-2023 | Jornay Pm |
| Shire North American Group INC | $43.04 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $42.61 | 2019-2021 | |
| Tris Pharma INC | $40.61 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $39.49 | 2025 | Xeomin |
| Abbvie INC. | $30.30 | 2022 | |
| Adlon Therapeutics L.P. | $29.66 | 2020-2021 | |
| Catalyst Pharmaceuticals, INC. | $27.70 | 2025 | |
| Biomarin Pharmaceutical INC. | $27.48 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $21.67 | 2025 | Daybue |
| Upsher-Smith Laboratories LLC | $16.98 | 2019 | |
| Collegium Pharmaceutical, INC. | $15.81 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $15.79 | 2019 | |
| Genentech USA, INC. | $15.59 | 2022 | |
| Ptc Therapeutics, INC. | $15.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ananthi Rathinam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.